Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous fecal microbiota transplantation (c771a1)
- Development stage
- Unknown
- Lead developer
- Otto Helve
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Autologous fecal microbiota transplantation (auto-FMT) is a microbial therapy that utilizes a patient's own fecal microbiota, collected and stored prior to antibiotic exposure, to restore gut microbiome homeostasis. In the clinical research led by Otto Helve, the microbiota is processed through lyophilization and encapsulated for oral administration following a course of antibiotics such as amoxicillin-clavulanate. The primary objective is to accelerate the recovery of intestinal microbial diversity and prevent antibiotic-associated dysbiosis by reintroducing the individual's unique baseline microbial community, thereby mitigating the risk of opportunistic infections and long-term microbiome disruption.
- Other names
- auto-FMTlyophilized capsulated autological fecal microbial transplant
Beyond the preview
Go deeper on autologous fecal microbiota transplantation (c771a1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous fecal microbiota transplantation (c771a1).